Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19
Effat Davoudi-Monfared, Hamid Rahmani, Hossein Khalili, et al.
Antimicrobial Agents and Chemotherapy (2020) Vol. 64, Iss. 9
Open Access | Times Cited: 287

Showing 1-25 of 287 citing articles:

Features, Evaluation and Treatment Coronavirus (COVID-19)
Marco Cascella, Michael Rajnik, Arturo Cuomo, et al.
StatPearls (2020)
Closed Access | Times Cited: 2796
Risk factors for severe and critically ill COVID‐19 patients: A review
Yadong Gao, Mei Ding, Xiang Dong, et al.
Allergy (2020) Vol. 76, Iss. 2, pp. 428-455
Open Access | Times Cited: 1282
Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 796
Pathophysiology of COVID-19-associated acute kidney injury
Matthieu Legrand, Samira Bell, Lui G. Forni, et al.
Nature Reviews Nephrology (2021) Vol. 17, Iss. 11, pp. 751-764
Open Access | Times Cited: 417
COVID-19: breaking down a global health crisis
Saad I. Mallah, Omar Ghorab, Sabrina Al-Salmi, et al.
Annals of Clinical Microbiology and Antimicrobials (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 305
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100794-100794
Open Access | Times Cited: 262
Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)
Abdul Aleem, Abdul Samad, Amy Slenker
(2021) Vol. 01, pp. 01-01
Closed Access | Times Cited: 242
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis
Santhamani Ramasamy, Selvakumar Subbian
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 3
Open Access | Times Cited: 234
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation
Fan Zhang, Joseph R. Mears, Lorien Shakib, et al.
Genome Medicine (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 184
ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection
Rajendra Karki, SangJoon Lee, Raghvendra Mall, et al.
Science Immunology (2022) Vol. 7, Iss. 74
Open Access | Times Cited: 169
I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People
Anna Julia Pietrobon, Franciane Mouradian Emidio Teixeira, Maria Notomi Sato
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 163
Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial
Hamid Rahmani, Effat Davoudi-Monfared, Anahid Nourian, et al.
International Immunopharmacology (2020) Vol. 88, pp. 106903-106903
Open Access | Times Cited: 158
Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis*
Eleni Karakike, Evangelos J. Giamarellos‐Bourboulis, Miltiades Kyprianou, et al.
Critical Care Medicine (2021) Vol. 49, Iss. 12, pp. 2042-2057
Open Access | Times Cited: 140
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Prasanna Jagannathan, Jason R. Andrews, Hector Bonilla, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 127
COVID‐19: immunopathology, pathophysiological mechanisms, and treatment options
Larissa E. van Eijk, Mathijs Binkhorst, Arno R. Bourgonje, et al.
The Journal of Pathology (2021) Vol. 254, Iss. 4, pp. 307-331
Open Access | Times Cited: 122
The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections
Ren‐Jun Hsu, Wei-Chieh Yu, Guan-Ru Peng, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 103
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
An overview on the treatments and prevention against COVID-19
Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 48
The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19
Gideon Schreiber
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 123
Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)
Yinghui Jin, Qingyuan Zhan, Zhiyong Peng, et al.
Military Medical Research (2020) Vol. 7, Iss. 1
Open Access | Times Cited: 110
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Yuwen Zhou, Yao Xie, Liansha Tang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 100
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial
André C. Kalil, Aneesh K. Mehta, Thomas F. Patterson, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 12, pp. 1365-1376
Open Access | Times Cited: 99
A humanized mouse model of chronic COVID-19
Esen Sefik, Benjamin Israelow, Haris Mirza, et al.
Nature Biotechnology (2021) Vol. 40, Iss. 6, pp. 906-920
Open Access | Times Cited: 94
Page 1 - Next Page

Scroll to top